Rasagiline

Back to search

Molecule Structure

Scientific Name

Rasagiline

Description of the Drug

Rasagiline is an irreversible inhibitor of monoamine oxidase used for the symptomatic management of idiopathic Parkinson’s disease as initial monotherapy and as adjunct therapy to levodopa.

Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01367

Brand Name(s)

Not Available

Company Owner(s)

Micro Labs Ltd, Apotex Inc, Alkem Laboratories Ltd, Teva Neuroscience Inc, Sandoz Inc, Watson Laboratories Inc, Dr Reddys Laboratories Ltd, Orbion Pharmaceuticals Private Ltd, Aurobindo Pharma Usa Inc, Indoco Remedies Ltd

Mechanism(s) Of Action

Target Name Target Type Action Type Target ChEMBL ID
Monoamine oxidase B SINGLE PROTEIN INHIBITOR CHEMBL2039

Unichem Links

SureChEMBL SCHEMBL74699
PharmGKB PA164764584
Human Metabolome Database HMDB0015454
DrugBank DB01367
PubChem: Thomson Pharma 15219503 15120458
PubChem 3052776
Mcule MCULE-4385913742
LINCS LSM-45548
Nikkaji J573.894F
PDBe RAU
BindingDB 10989
EPA CompTox Dashboard DTXSID3041112
DrugCentral 3521
Brenda 143736 135328 174632 163183 4421
ChemicalBook CB2459598
Guide to Pharmacology 6641
rxnorm RASAGILINE
ChEBI 63620
ZINC ZINC000019875504